Erkut Borazanci
HonorHealth Research Institute · Scottsdale Healthcare Hospitals DBA HonorHealth
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Erkut Borazanci as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:42 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05229588 · Lurbinectedin in Patients With Advanced Gastrointestinal Malignancies With DNA Repair MutationsHonorHealth Research Institute · completed · Gastrointestinal Malignancies · principal investigator
- Ph2NCT05216120 · Pemigatinib in Subjects With Adenosquamous Carcinoma of the PancreasHonorHealth Research Institute · withdrawn · Pancreas Cancer · principal investigator
- Ph2NCT05068752 · Phase II Trial of Vemurafenib and Sorafenib in Pancreatic CancerHonorHealth Research Institute · completed · Pancreas Cancer · principal investigator
- Ph2NCT04669197 · Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydroxychloroquine as Treatment in Untreated Pancreas CancerHonorHealth Research Institute · completed · Untreated Resectable Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma · principal investigator
- Ph1/Ph2NCT04203641 · L-DOS47 Plus Doxorubicin in Advanced Pancreatic CancerHelix BioPharma Corporation · terminated · Pancreas Cancer · principal investigator
- Ph2NCT03415854 · Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD)HonorHealth Research Institute · completed · Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Pancreatic Adenocarcinoma · principal investigator
- Ph2NCT03138720 · Pre-operative Treatment for Patients With Untreated Pancreatic CancerHonorHealth Research Institute · completed · Resectable Pancreatic Cancer, Unresectable Pancreatic Cancer, Pancreatic Adenocarcinoma · principal investigator
- Ph2NCT03117920 · A Phase II, International Open Label Trial of Minnelide™ in Patients With Refractory Pancreatic CancerMinneamrita Therapeutics LLC · completed · Pancreatic Cancer · principal investigator
- N/ANCT02790944 · Utilizing a Multi-gene Testing Approach to Identify Hereditary Pancreatic CancerAmbry Genetics · completed · Pancreatic Ductal Adenocarcinoma · principal investigator
- Ph2NCT02754726 · Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal AdenocarcinomaHonorHealth Research Institute · completed · Untreated Metastatic Pancreatic Ductal Adenocarcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:42 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:42 UTC. The ranking covers the 200 most relevant of 18 PubMed records, and a shared surname and initials can bring in a namesake. All 18 on PubMed
- BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial.Nat Med · 2020493 citationsRCR 19.5
- 266 citationsRCR 9.4
- Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer.J Immunother Cancer · 2021190 citationsRCR 9.7
- U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors.Clin Cancer Res · 202095 citationsRCR 3.2
- Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial.Clin Cancer Res · 202190 citationsRCR 4.3
- 70 citationsRCR 2.2
- Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors.ESMO Open · 202237 citationsRCR 2.2
- Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors.Clin Cancer Res · 202236 citationsRCR 2.5
- 29 citationsRCR 1.5
- 28 citationsRCR 4.2